Bacteria can transmit memory across generations so their descendants will know how to attach themselves to surfaces and form communities…
Articles by Patricia Inácio, PhD
Ibuprofen does a good job of fighting bacteria in cystic fibrosis (CF) patients’ lungs, including two key threats, Pseudomonas aeruginosa and Burkholderia, a study…
Vertex Pharmaceuticals launched the first Phase 3 clinical trial investigating the triple combination therapy of VX-659, tezacaftor (VX-661), and…
AzurRx BioPharma announced that its clinical trial testing MS1819-SD as a replacement enzyme therapy for exocrine pancreatic insufficiency (EPI) associated…
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Symdeko (tezacaftor/ivacaftor and ivacaftor) as a therapy for…
Vertex Pharmaceuticals will advance to the next clinical-trial stage two therapies designed to correct faulty mechanisms underlying cystic fibrosis. The…
Volatile molecules present in bronchoalveolar lavage (BAL) samples from cystic fibrosis (CF) patients may help identify those infected with Pseudomonas aeruginosa…
AIT Therapeutics’ nitric oxide mist led to a 65 percent reduction in cystic fibrosis patients’ airway bacteria and an…
Using a cystic fibrosis patient’s tissue to grow mini-guts in a lab has become easier and is available to…
When two channels that are supposed to move chloride and sodium ions out of cells in the lungs fail to…